The use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis

Background. The assessment of organ damage in patients with systemic sclerosis (SSc) is challenging. The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) proposed in 2019 has not been sufficiently studied and requires testing for wider use.The aim of the study was to examine the progres...

詳細記述

書誌詳細

主要な著者:	L. P. Ananyeva, V. V. Babak, A. D. Koltakova, O. A. Koneva, O. V. Desinova, M. N. Starovoytova, O. B. Ovsyannikova, R. U. Shayakhmetova
フォーマット:	Artigo
言語:	Russo
出版事項:	IMA PRESS LLC 2025-03-01
シリーズ:	Научно-практическая ревматология
主題:	прогрессирующий системный склероз индекс повреждения sctc-di
オンライン･アクセス:	https://rsp.mediar-press.net/rsp/article/view/3704
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!